Probiotix Health PLC Launch of cholesterol reducing yoghurt (3037N)
31 5월 2022 - 3:01PM
UK Regulatory
TIDMPBX
RNS Number : 3037N
Probiotix Health PLC
31 May 2022
31 May 2022
ProBiotix Health plc
( "ProBiotix" or the "Company")
Launch of cholesterol reducing yoghurt
A new probiotic yoghurt Yo-Life(R) with LP(LDL) (R) for
cholesterol reduction launched in Uruguay
ProBiotix Health Plc (AQSE: PBX), a life sciences company
developing clinically proven probiotic solutions to tackle chronic
lifestyle diseases like high cholesterol, high blood pressure and
atherslorosis, announces that its partner, Granja Pocha has
launched a probiotic functional yoghurt brand, Yo-Life(R),
containing ProBiotix's patented cholesterol reducing Lactobacillus
plantarum strain (LP(LDL) (R)), in Uruguay after a two and a half
year development process.
LP(LDL) (R) was identified for its ability to reduce
cholesterol, survive in the gut and for its long shelf life, by
screening over 4,000 probiotic species in a pharma-based systematic
approach. LP(LDL) (R) has six publications on its mechanisms of
action and three peer reviewed publications demonstrating
reductions in Total Cholesterol of up to 34.6%, LDL-Cholesterol by
28.4%, and apoB (biomarker of atheroschlerosis) by 28.6%, and is
protected by an extensive patent portfolio. LP(LDL) (R) was
recognised as Generally Recognized As Safe ("GRAS") by an
independent Expert GRAS Panel in the United States. GRAS is a
United States Food and Drug Administration (FDA) designation that
any substance added to food is considered safe by experts.
Granja Pocha is one of Uruguay's largest and most respected
dairy producers, specialising in the sale of products such as milk,
cheeses and yogurts under its Colonial brand. The work carried out
by Granja Pocha is a significant milestone, as it extends the use
of LP(LDL) (R) into functional dairy foods with a health claim
which may be replicated in other territories and other functional
foods on a global scale.
Yo-Life (R), is a science-backed innovation brand that has been
developed to help reduce cardiovascular disease risk, one of the
leading causes of death in South America, by lowering harmful
cholesterol and blood pressure.
The launch follows over two and a half years of product
development with Granja Pocha and manufacturing partners CSL/Sacco
to ensure the addition of LP(LDL) (R) to yoghurt does not change
its taste, texture, or shelf life. LP(LDL) (R) is active in
milligram amounts which provides a cost advantage over stanols or
sterols which typically require doses of 2gms.
The global probiotics market is forecast to reach $94.48 billion
by 2027, at a CAGR of 7.9%, dominated by the use of probiotics in
food and beverages, particularly dairy, and and using clinically
proven probiotics as a natural replacement for pharmaceutical
solutions (Fortune Business insights, 2022).
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health Plc
said: "This is significant Company milestone and to our knowledge,
the first time a cholesterol reducing probiotic has been launched
in a commercial yoghurt with a pack claim stating: "helps reduce
cholesterol". The dairy industry is a highly commoditised industry
and looking for innovation and functional ingredients to
differientiate from competition and to maintain it's current growth
trajectory. The launch of Yo-Life(R) containing LP(LDL) (R) will
facilitate the entry to a market where volumes and sales are
significantly higher than the dietary supplement industry.
ProBiotix is currently working with a number of major food and
beverage partners who value innovation, to extend LP(LDL) (R) into
new product ranges and territories and help people around the world
reduce their cholesterol levels and risk of cardiovascular
disease."
For further information, please contact:
ProBiotix Health plc https://probiotixhealth-ir.com/
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Peterhouse Capital Ltd (AQSE Corporate Adviser Tel: 020 7220 0500
and Broker)
Mark Anwyl Tel: 020 7469 0930
Duncan Vasey
Walbrook PR Ltd probiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About ProBiotix - www.probiotixhealth-ir.com
ProBiotix Health was established by OptiBiotix Health Plc to
develop probiotics to tackle cardiovascular disease and other
lifestyle conditions which are affecting growing numbers of people
across the world. Since its creation, ProBiotix has become a global
leader in microbiome modulating probiotics for use in functional
foods, supplements and biotherapeutics.
Independent clinical studies have shown that ProBiotix ' s
principal product, LP(LDL) (R), which is protected by an extensive
patent portfolio, can reduce key cardiovascular risk biomarkers:
Total Cholesterol of up to 34.6%, LDL-Cholesterol by 28.4%, and
apoB (biomarker of atheroschlerosis) by 28.6%. Since launching its
CholBiome(R) products containing LP(LDL) (R) in May 2017, ProBiotix
has signed over 41 agreements and its products are now
commercialised in 60 countries.
LP(LDL) (R) was designated Generally Recognized As Safe ("GRAS")
by an independent Expert GRAS Panel in the United States in
February 2019, which extends its applications from use as a
supplement to use as a functional ingredient in a wide range of
food, dairy, and beverage products in the USA.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXWPUUCAUPPGQU
(END) Dow Jones Newswires
May 31, 2022 02:01 ET (06:01 GMT)
Probiotix Health (AQSE:PBX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Probiotix Health (AQSE:PBX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
